ASX Health Stocks: Big tick for Cynata's stem-cell therapy

New study shows Cynata’s therapy improves pulmonary fibrosis
Nasal spray ED treatment now available at Kangaroo Point Medical Centre
Singular Health integrates new dental AI model into 3Dicom system

CYP’s therapy improves pulmonary fibrosis: study

Cynata Therapeutics (ASX:ACYP), a clinical-stage biotech specialising in cell-based therapies, has made a significant announcement regarding its research on Cymerus MSC (mesenchymal stem cell).

The company has just published a study in the peer-reviewed journal Biomedicine & Pharmacotherapy, which explores the application of its off-the-shelf iPSC-derived MSC therapy in a preclinical model of pulmonary fibrosis.

iPSC is short for induced pluripotent stem cells, which are a type of stem cell made by reprogramming regular adult cells, like skin or blood cells, to behave like very versatile stem cells.

This research was conducted by Professor Chrishan Samuel, a Monash Biomedicine Discovery Fellow and Head of the Fibrosis Laboratory at Monash University.

The study utilised a mouse model where pulmonary fibrosis was induced by bleomycin, a method commonly used to replicate the features of idiopathic pulmonary fibrosis (IPF) in humans.

IPF is a severe and progressive lung disease marked by chronic scarring and stiffening of the lungs, which leads to progressively worsening difficulty in breathing. With no known cure, IPF often results in a median survival rate of just two to five years after diagnosis.

The results from the study indicated that Cymerus MSCs had a profound impact on the pulmonary fibrosis model.

The treatment was shown to reduce lung inflammation and epithelial damage, demonstrating its ability to alleviate some of the harmful effects of the disease.

It also decreased the levels of pro-inflammatory cytokines while promoting the expression of anti-inflammatory cytokines, thus aiding in the reduction of inflammation.

Additionally, the MSCs were effective in reducing measures of lung fibrosis, suggesting a significant impact on the scarring process.

Kangaroo Point Medical Centre begins Spontan prescriptions

LTR Pharma (ASX:LTP) has announced that a second Australian expert in men’s health is now authorised to prescribe Spontan, a revolutionary nasal spray treatment for erectile dysfunction (ED).

Dr Tom Silva, a senior lecturer at the University of Queensland and director of Kangaroo Point Medical Centre, is the latest to start offering Spontan to his patients.

Kangaroo Point Medical Centre is a leading healthcare facility in Brisbane, specialising in ED and men’s health.

Spontan is noted for its quick action and lower side-effect profile compared to other treatments.

“Spontan meets the needs of my patients where regular PDE5 inhibitor tablets do not. Its fast onset of action, ease of use and improved side-effect profile make it a valuable addition to our treatment options for erectile dysfunction,” said Silva.

The nasal spray uses a lower dose of the active ingredient, which may lower the risk and duration of side effects compared with oral table options, while still being effective.

“We are thrilled to see Spontan being utilised by medical experts like Dr Silva,” said LTR Pharma Chairman, Lee Rodne.

“This represents another significant step in our strategy to introduce Spontan to the market through a carefully managed approach working with knowledgeable medical practitioners.”

Singular integrates new dental AI model

Meanwhile, Singular Health Group (ASX: SHG) has reached a major milestone by successfully integrating its first third-party AI model into the 3Dicom system.

This integration, in collaboration with Relu BV, enables advanced dental imaging capabilities, including AI-driven segmentation and 3D printing.

The company has also launched a Public API to simplify the addition of other AI models into its platform, moving towards a comprehensive online marketplace for AI-driven dental solutions.

The integration of Relu’s dental AI model allows for detailed dental analysis and visualisation in the cloud, which can be used for educational purposes, pre-operative planning, and creating 3D printed models of patient anatomy.

This development has generated significant interest from potential clients, including educational institutions, dental practices, and research organisations across Australia, Europe, and the USA.

Singular Health is now working on finalising commercial agreements and will soon offer these AI tools on a pay-per-use basis.

The company will provide more updates as new commercial opportunities arise and agreements are reached.

At Stockhead we tell it like it is. While LTR Pharma is a Stockhead advertiser at the time of writing, it did not sponsor this article.